# FAQ: Research Peptide Fundamentals — Peptide Biotechnology > Frequently asked questions about BPC-157, Ipamorelin, Retatrutide and Thymosin Alpha-1 — cited, plain-English answers covering mechanism, safety, regulatory status and the limits of the evidence. Honest answers to the most common questions about the four peptides on this desk. ## What does BPC-157 do in the body? In animal models, BPC-157 appears to promote tissue repair and protect cells from damage — which is where the "body protection" name comes from. The most consistently documented mechanism is angiogenesis: it upregulates the VEGFR2 receptor and activates downstream nitric-oxide signaling, which stimulates new blood-vessel growth into damaged tissue [4]. Additional proposed routes include cell-migration signaling (FAK-paxillin) and growth-hormone-receptor sensitization in tendon fibroblasts. In humans, there are only a handful of tiny pilot reports — large controlled trials have not been done — so what it does in people, at what scale and with what safety profile, remains genuinely unknown [2]. ## Is BPC-157 a growth hormone? No. BPC-157 is not a hormone and does not belong to the growth-hormone class. It is a cytoprotective peptide derived from a sequence in gastric juice protein. While it may sensitize the growth-hormone receptor in tendon cells at the tissue level, it does not trigger systemic GH release — that is the mechanism of secretagogues like Ipamorelin. Describing BPC-157 as a growth hormone is a common online error not supported by the published literature [2][4]. ## Does BPC-157 work immediately? Pharmacokinetic data from rats and dogs show BPC-157 has a very short elimination half-life (under 30 minutes) and breaks down rapidly into amino-acid metabolites [3]. Any direct cellular effects would therefore depend on brief exposure windows. In animal healing models, effects on tissue are observed over days and weeks, not within minutes. Anecdotal reports from research-use communities sometimes describe effects within one to three weeks, but the thin human evidence base makes it impossible to say with confidence how quickly or whether effects would appear in people. ## Does BPC-157 damage the liver? Nothing in the published literature documents hepatotoxicity from BPC-157. The 2025 first-in-human intravenous safety pilot (n=2 adults, up to 20 mg) found no measurable changes in hepatic biomarkers [1]. Animal studies have not flagged liver damage as a finding. That said, the human dataset is extremely thin, and the absence of documented liver damage in two people and animal work is not the same as a confirmed clean hepatic safety profile in humans. No large trial data exist. ## What is ipamorelin? Ipamorelin is a synthetic five-amino-acid peptide that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering a pulse of growth hormone release. It was characterized in 1998 as the first highly selective growth hormone secretagogue — producing potent GH release without meaningfully raising cortisol, ACTH or prolactin, even at doses far exceeding its effective concentration [11]. It has never been approved as a drug; its one published Phase 2 human trial did not meet its primary endpoint [8]. ## What does ipamorelin do for you? In the one controlled human setting where ipamorelin was studied — a Phase 2 trial in patients recovering from bowel surgery — it did not significantly reduce the time to tolerated food, its primary endpoint [8]. Its human pharmacokinetic profile shows it produces a discrete GH pulse peaking around 40 minutes after dosing, with a two-hour terminal half-life [9]. In animals it increased bone growth rate at studied doses [10]. Anecdotal community reports describe deeper sleep, faster physical recovery and gradual body-composition changes, but these are self-reported impressions from research-use contexts, not outcomes from controlled human trials. ## What is ipamorelin peptide? Ipamorelin is classified as a growth hormone secretagogue — a synthetic compound that mimics ghrelin's action at the GHS-R1a receptor to stimulate the pituitary to release growth hormone. Its amino-acid sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. The unusual amino acids (D-isomers, naphthylalanine) make it resistant to enzyme breakdown and extend its activity. It belongs to the same receptor-class as GHRP-6 and GHRP-2 but is distinguished by its lack of off-target cortisol and prolactin elevation [11]. It is not an approved drug, not a supplement, and not the same as the CJC-1295 peptide it is often used alongside. ## What are the risks of ipamorelin? Key risks documented or inferred from the literature: GH-axis stimulation raises theoretical concern about IGF-1 and tumor promotion in those with active or occult malignancy [11]. GH is a counter-regulatory hormone that reduces insulin sensitivity, and ipamorelin also directly stimulates pancreatic islet cells — a dual metabolic effect with unpredictable net impact in those with existing insulin dysregulation. A related GHS-R1a compound caused dose-dependent myocardial changes in a 28-day rat study, raising a class-level cardiac caution for chronic use [7]. Long-term human safety data simply do not exist. Additionally, ipamorelin is prohibited in sport under WADA S2 at all times, and research-grade material from unregulated suppliers has unverified purity and sterility [8]. ## What does retatrutide do? Retatrutide simultaneously activates three hormone receptors — GLP-1, GIP and glucagon — in a single molecule. This triple-receptor agonism suppresses appetite, augments glucose-dependent insulin secretion, and adds energy expenditure through the glucagon arm [13]. In a 48-week Phase 2 obesity trial it produced a mean weight loss of approximately 24% — the largest pharmacologically generated weight reduction in a formal trial to date [16]. It also significantly reduced liver fat in participants with metabolic steatotic liver disease [15]. It is investigational and not yet approved. ## How does retatrutide work? Retatrutide is a once-weekly injectable peptide built on a GIP-based backbone acylated for albumin binding and extended half-life. Its GLP-1 receptor arm slows gastric emptying and reduces appetite through central and peripheral signaling. Its GIP receptor arm amplifies glucose-dependent insulin secretion and may contribute to energy storage effects. Its glucagon receptor arm increases energy expenditure through thermogenic and lipolytic pathways. Cryo-EM structural work has resolved how the single molecule engages all three receptor complexes simultaneously, showing distinct binding conformations at each [14]. The interaction between the arms — particularly glucagon-driven energy expenditure countered by GLP-1 and GIP-mediated insulin augmentation — is what distinguishes it mechanistically from single or dual agonists [13][16]. ## How to reconstitute retatrutide? This desk does not provide reconstitution instructions. Retatrutide is an investigational drug; the verified compound exists only in clinical trial settings with pharmaceutical-grade manufacturing and clinical oversight. Research-labeled material sold outside trials has no confirmed identity or sterility, and handling instructions for that material are outside the scope of this literature digest. This site does not give preparation, dosing or handling guidance for any compound. ## Is retatrutide FDA approved? No. As of mid-2026, retatrutide has not been approved by the FDA or any other regulatory agency. It remains under investigation in Phase 3 trials (the TRIUMPH program and dedicated cardiovascular and kidney outcomes trials). All published efficacy and safety data are from Phase 2 studies conducted by Eli Lilly and Company. It is an investigational drug that should not be conflated with approved incretin therapies [13][16]. ## What is thymosin alpha 1? Thymosin Alpha-1 is a 28-amino-acid peptide naturally produced in the thymus — the gland that educates immune cells. Its synthetic form (thymalfasin) is approved as a drug in more than 35 countries for viral hepatitis and other immune conditions, but it is not FDA-approved in the United States [19]. It is strictly distinct from thymosin beta-4 (and its fragment TB-500) — a different protein with a different sequence, mechanism and therapeutic focus — and from thymulin, a zinc-dependent thymic nonapeptide. The naming overlap is a frequent source of confusion. ## What does thymosin alpha 1 do? Thymosin Alpha-1 acts at the innate-adaptive immune interface. It binds Toll-like receptors TLR2 and TLR9 on dendritic cells and monocytes, promoting their maturation, upregulating HLA-DR expression (antigen presentation) and stimulating IL-12 production, which drives Th1-polarized immune responses [21][22]. In people with severely depleted T-cell counts, it has been shown to increase circulating T-cell numbers and reverse markers of T-cell exhaustion (PD-1 and Tim-3 on CD8+ cells) [20]. It also generates regulatory T cells through the IDO-tryptophan pathway, giving it a dual immunostimulatory and regulatory profile. ## What is thymosin alpha 1 used for? Internationally, thymalfasin is approved as a drug for chronic hepatitis B and C (where immune impairment drives viral persistence), immune restoration in immunocompromised patients, and as an adjuvant in some oncology protocols in the countries that have licensed it [19][21]. Clinical research has also studied it in sepsis, COVID-19 and as a vaccine adjuvant. The largest sepsis trial (TESTS, Phase 3, 1,106 patients, 2025) found no significant mortality benefit [18], tempering earlier smaller signals. In the United States its clinical use is outside approved drug labeling. ## Is thymosin alpha 1 FDA-approved? No. Thymosin Alpha-1 (thymalfasin) is not FDA-approved for marketing in the United States. It is approved as a drug in roughly 35 other countries but has no US marketing authorization. US use is limited to investigational contexts or compounding, with the FDA's review of related bulk drug substances for compounding remaining unresolved. Its international approved-drug status is in hepatitis and immune-reconstitution settings, not as a general wellness product [19]. --- A desk for reading, not prescribing — literature summaries of research peptide biology, cited to the primary source.